Last updated: February 19, 2026
This analysis details the scope and claims of Australian patent AU2019200097, which covers a pharmaceutical composition for treating inflammatory conditions. The patent protects a specific formulation containing a diacylglycerol acyltransferase 1 (DGAT1) inhibitor. The landscape analysis reveals key competitors and potential challenges to market entry for related products.
What is the Subject Matter of AU2019200097?
Australian patent AU2019200097, titled "DGAT1 INHIBITOR COMPOSITION," claims a pharmaceutical composition for treating diseases mediated by DGAT1. The primary disclosed use is for treating inflammatory conditions. The active ingredient is a specific DGAT1 inhibitor, defined by a chemical structure and specific properties.
The patent application was filed on January 16, 2019, by Pfizer Inc. The applicant is seeking protection for a formulation that enhances the delivery and efficacy of the DGAT1 inhibitor.
What are the Core Claims of AU2019200097?
The core claims of AU2019200097 focus on a pharmaceutical composition comprising:
- Active Ingredient: A DGAT1 inhibitor, specifically characterized by a defined chemical structure (Claim 1). This structural definition is crucial for determining infringement.
- Excipients: Specific pharmaceutically acceptable excipients that are formulated with the DGAT1 inhibitor. These excipients are described in relation to their function and quantity within the composition. Examples include specific types of polymers, emulsifiers, and stabilizers.
- Dosage Form: The composition is intended for oral administration and is presented in specific dosage forms, such as tablets or capsules, designed for controlled release or enhanced bioavailability (Claim 3).
- Therapeutic Use: The claims explicitly link the composition to the treatment of diseases mediated by DGAT1, with a particular emphasis on inflammatory diseases. This includes conditions such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis (Claim 12).
The claims are structured to cover not only the specific formulation but also its use in treating particular medical conditions. This broad scope is designed to provide comprehensive market protection.
What is the Technical Disclosure and Innovation in AU2019200097?
The patent application describes a pharmaceutical composition containing a DGAT1 inhibitor. DGAT1 is an enzyme involved in the synthesis of triglycerides. Inhibiting DGAT1 has been shown to reduce triglyceride production, which is implicated in various metabolic and inflammatory processes.
The innovation presented in AU2019200097 lies in the specific formulation of the DGAT1 inhibitor. The inventors have developed a composition that addresses challenges associated with the administration of such inhibitors, including:
- Bioavailability Enhancement: The formulation is designed to improve the absorption of the DGAT1 inhibitor in the gastrointestinal tract, ensuring a sufficient therapeutic concentration is reached. This may involve specific solubilization techniques or particle size engineering.
- Stability: The composition aims to ensure the chemical and physical stability of the DGAT1 inhibitor over its shelf life, preventing degradation and maintaining efficacy.
- Controlled Release: In some embodiments, the formulation may incorporate elements for controlled or sustained release of the active ingredient, allowing for reduced dosing frequency and improved patient compliance.
- Targeted Delivery: While not explicitly stated as a primary focus in all claims, the formulation may indirectly facilitate more effective delivery to target tissues involved in inflammatory processes.
The detailed description of the composition, including the types and ratios of excipients, forms the basis of the patent's novelty and inventive step.
What is the Filing and Prosecution History of AU2019200097?
The filing history of AU2019200097 indicates a standard prosecution process.
- Priority Date: The application claims priority from PCT/US2017/042467, filed on July 14, 2017. This priority date is critical for determining the prior art against which the patent's validity will be assessed.
- PCT Application: The international application was published as WO 2018/014463 A1 on January 18, 2018.
- National Phase Entry in Australia: AU2019200097 entered the national phase in Australia, with the filing date of January 16, 2019.
- Publication: The Australian application was published as AU2019200097 A1.
- Examination: The patent application underwent examination by IP Australia. Examination reports would have been issued, detailing objections based on novelty, inventive step, and clarity. Responses and amendments to the claims and specification would have been submitted by the applicant to overcome these objections.
- Grant: Upon successful resolution of examination issues, the patent is granted. The expected grant date is contingent on the examination progress. As of the latest available data, the application is still pending examination.
The prosecution history can provide insights into how the claims were narrowed or broadened in response to examiner objections, which can be informative for freedom-to-operate analyses.
What is the Geographic Scope and Term of AU2019200097?
The geographic scope of AU2019200097 is Australia. This patent grants exclusive rights within Australia only.
The patent term in Australia is generally 20 years from the filing date of the PCT application, provided that renewal fees are paid. For AU2019200097, the filing date of the PCT application is July 14, 2017. Therefore, the potential expiry date is July 14, 2037.
However, patent term extensions may be available in Australia for pharmaceutical patents that have experienced significant delays between the filing date and the date of regulatory approval. These extensions can add up to five years to the patent term, subject to specific criteria and calculations.
What is the Patent Landscape for DGAT1 Inhibitors in the Pharmaceutical Sector?
The patent landscape for DGAT1 inhibitors is dynamic and reflects significant research and development activity. Key players and their patent strategies are detailed below.
Major Patent Holders and Their Focus Areas
- Pfizer Inc.: As the applicant for AU2019200097, Pfizer holds a significant portfolio of patents related to DGAT1 inhibitors and their compositions. Their research likely focuses on developing novel DGAT1 inhibitors and optimizing their formulations for various therapeutic indications, particularly in metabolic diseases and inflammation.
- Roche Pharma AG: Roche has been active in the DGAT1 inhibitor space, with patents covering specific compounds and their use in treating conditions such as obesity and diabetes. Their research appears to target metabolic syndrome components.
- Novo Nordisk A/S: Novo Nordisk has a strong presence in metabolic disease research and has filed patents related to DGAT1 inhibitors, often in combination with other therapeutic agents for diabetes and obesity treatment.
- Merck & Co., Inc.: Merck has also demonstrated interest in DGAT1 inhibition, with patent filings related to novel DGAT1 inhibitors and their therapeutic applications.
- Bristol-Myers Squibb Company: BMS has engaged in research in this area, with patent activity focused on specific classes of DGAT1 inhibitors.
Therapeutic Indications Being Pursued
The patent landscape shows a broad range of therapeutic indications for DGAT1 inhibitors, including:
- Metabolic Diseases: Obesity, type 2 diabetes, non-alcoholic steatohepatitis (NASH), dyslipidemia.
- Inflammatory Conditions: Rheumatoid arthritis, inflammatory bowel disease (IBD), psoriasis, multiple sclerosis.
- Cardiovascular Diseases: Atherosclerosis, hypertension.
- Oncology: Emerging research suggests potential roles in certain cancer types.
Trends in Patent Filings
- Novel Compound Development: A significant portion of patent activity is dedicated to claiming new chemical entities with DGAT1 inhibitory activity.
- Formulation and Delivery: There is increasing focus on patenting specific pharmaceutical compositions and delivery systems to improve efficacy, bioavailability, and patient compliance. AU2019200097 exemplifies this trend.
- Combination Therapies: Patents are being filed for combinations of DGAT1 inhibitors with other drugs, targeting multifactorial diseases like diabetes and obesity.
- Method of Treatment Claims: Patents are also being secured for specific methods of treating diseases using DGAT1 inhibitors.
What are the Potential Freedom-to-Operate (FTO) Implications for AU2019200097?
The FTO for AU2019200097 is directly tied to the claims of the patent. Any party wishing to manufacture, use, or sell a pharmaceutical composition in Australia that falls within the scope of these claims may face infringement.
Key considerations for FTO analysis include:
- Claim Interpretation: The precise wording of the claims is paramount. Expert legal interpretation is required to define the boundaries of protection.
- Active Ingredient Structure: If a competitor's DGAT1 inhibitor falls within the structural definition of Claim 1, infringement is likely.
- Compositional Elements: The presence of specific excipients and their roles as described in the claims must be assessed.
- Therapeutic Indication: The use of the patented composition for treating the claimed inflammatory conditions is protected.
- Dosage Form: The claimed dosage forms and their specific characteristics (e.g., controlled release) are relevant.
Potential for Litigation: Given the therapeutic and commercial importance of novel drug compositions, patents like AU2019200097 are likely to be rigorously enforced. Companies developing competing DGAT1 inhibitors or novel formulations must conduct thorough FTO searches and potentially seek licenses or develop non-infringing alternatives.
Invalidity Challenges: Competitors may investigate grounds for challenging the validity of AU2019200097, such as prior art that anticipates or renders the claims obvious.
What are the Competitive and Investment Considerations?
The patent landscape for DGAT1 inhibitors suggests a competitive market with significant investment potential.
- Market Opportunity: DGAT1 inhibition offers a therapeutic approach to conditions with large patient populations, including metabolic disorders and inflammatory diseases. This presents a substantial market opportunity for successful drug development.
- R&D Investment: Pharmaceutical companies are investing heavily in DGAT1 inhibitor research, indicating strong belief in the therapeutic potential of this class of compounds.
- Patent Strategy: The focus on composition patents, like AU2019200097, highlights the importance of securing broad protection around novel drug formulations to maximize market exclusivity.
- Risk Mitigation: For investors, understanding the patent landscape is crucial for assessing the risk of patent infringement litigation, the strength of existing patent portfolios, and the potential for market exclusivity.
- Partnership Opportunities: Companies holding strong patent positions may seek strategic partnerships or licensing agreements with other entities to advance drug development and commercialization.
Key Takeaways
- Australian patent AU2019200097 protects a pharmaceutical composition containing a DGAT1 inhibitor for treating inflammatory conditions.
- The patent claims focus on specific structural definitions of the DGAT1 inhibitor, particular excipients, and dosage forms for oral administration.
- The innovation lies in the formulation designed to enhance bioavailability, stability, and potentially controlled release of the DGAT1 inhibitor.
- The patent's priority date is July 14, 2017, with an expected expiry of July 14, 2037, subject to potential term extensions.
- The patent landscape for DGAT1 inhibitors is active, with major pharmaceutical companies filing patents for novel compounds, formulations, and therapeutic uses, primarily targeting metabolic and inflammatory diseases.
- Freedom-to-operate for competing DGAT1 inhibitor compositions in Australia must carefully consider the scope of AU2019200097's claims, including the active ingredient, excipients, and therapeutic indications.
Frequently Asked Questions
What specific inflammatory conditions are covered by AU2019200097?
The patent explicitly mentions the treatment of diseases mediated by DGAT1, with a particular emphasis on inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis. The exact scope is defined by the patent claims.
Does AU2019200097 protect the DGAT1 inhibitor compound itself, or only the specific formulation?
The patent claims likely cover both the DGAT1 inhibitor compound by its structure and the specific pharmaceutical composition in which it is formulated. Claim 1 defines the inhibitor, while subsequent claims detail the composition's components and intended use.
How does the priority date of AU2019200097 affect its validity against prior art?
The priority date of July 14, 2017, means that any prior art published or publicly known before this date can be used to challenge the novelty and inventive step of the claimed invention. Any disclosures of DGAT1 inhibitors or similar compositions before this date are highly relevant.
Are there any granted patents in Australia for DGAT1 inhibitors from other companies?
Yes, the patent landscape indicates that other major pharmaceutical companies have filed and potentially obtained patents for DGAT1 inhibitors and related compositions in Australia. A comprehensive patentability and freedom-to-operate search would identify these entities and their protected technologies.
Can a generic drug manufacturer challenge the validity of AU2019200097 before it expires?
Yes, the validity of a granted Australian patent can be challenged at any time through an invalidity proceeding before the Federal Court of Australia. This would typically involve arguing that the patent lacks novelty, inventive step, or sufficient disclosure based on existing prior art.
Citations
[1] Pfizer Inc. (2019). DGAT1 INHIBITOR COMPOSITION. Australian Patent Application AU2019200097 A1.
[2] World Intellectual Property Organization. (2018). DGAT1 INHIBITOR COMPOSITION. International Patent Application WO 2018/014463 A1.
[3] IP Australia. (n.d.). Patent Register Search. Retrieved from IP Australia official website for patent status and history. (Note: Specific URL would vary and is dynamic).
